
Einigkeit und Recht und Freiheit.

MD, #oncologist #GUcancer, #clinicalresearch #oceanlover #surfingmom @CHRU_Brest @CHQuimper 🇩🇪🇫🇷 🇪🇺 🇮🇱views are mine

Einigkeit und Recht und Freiheit.

Offer enfortumab vedotin in combination with pembrolizumab as first line treatment to patients with advanced/metastatic UTUC. #UTUC #EAUguidelines uroweb.org/guidelines/upper-…

I’m Kamala Harris, and I’m running for President of the United States.

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-receive…

Unser Bundestrainer, Herr Julian Nagelsmann, mit einer ganz persönlichen Botschaft an die beiden Parteien BSW und AfD. Und an alle anderen Populisten da draußen.... #WeAreOne #DeutschlandEinigVaterland

Great job! That’s scientific reporting at its finest 🤣🫶🏻
Not sure who deserves credit for this, but enjoy! #ASCO24

Trump posted today, “IF THIS CAN HAPPEN TO ME, IT CAN HAPPEN TO ANYONE!” I’ll remember that the next time I cheat on my third wife with a porn star and have to pay her off because I’m running for President.



Magnifique journée pour l'inauguration de notre nouvel Institut de Cancerologie et d'Imagerie, l'ICI, tourné vers l'innovation et l'excellence pour tous les bretons du territoire !
This tweet is unavailable

Honored to be invited at #EAU2024 as a medical oncologist 👩🏼⚕️Looking forward to see my #urologist friends in Paris! #prostatecancer #bladdercancer #clinicalresearch #cancerfighter #BRCA #FGFR #testing
Join us for an interactive live seminar on ‘Targeted therapies in GU Cancers’ from #EAU2024. Explore biomarker breakthroughs, BRCA mutations in mCRPC, and case studies in precision medicine. Register free here👉 ecancer.org/EAULive #EAU2024 @FSchlurmann @evacomperat @Roubaud

The final results of #POUT adjuvant trial in Upper Tract Urothelial cancer (UTUC) adjuvant trial are now published in @JCO_ASCO. This is a landmark study in the field and @AlisonBirtle + team should be celebrated. 5-year DFS (1EP): 62% vs. 45%, HR 0.55 (95% CI, 0.38-0.80, p=.001) 5-year OS: 66% vs. 57%, uHR = 0.68 (95% CI, 0.46 to 1.00, P = .049) No differences in QoL

Membres #AFU : Retrouvez ce soir un canal AFU spécial "Cancer de la prostate métastatique hormonosensible - Place du triplet en 2023". Merci à notre partenaire @Bayer_FR . 🎤 Avec @MRoupret @stephane_supiot @FSchlurmann et @CharlesDariane.

The reality of women under Islamic leadership 💔 #WomanLifeFreedom

JUST IN: @US_FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors! A great day for the field and a new option for our Kidney Cancer patients!!!! Via @ASCO #FDAAlerts @OncoAlert Study presented at @myESMO #ESMO3 by @AlbigesL

Festival Nova : l'horreur vue de l'intérieur Le reportage en entier : youtube.com/watch?v=730JnX7C…